Larvol Delta - Anokion-Announces-New-Data-from-the-Phase-1-MoveSit-Study-Supporting-ANK700-as-a-Novel-Potential-Disease-Modifying-Treatment-for-RelapsingRemitting-Multiple-Sclerosis

ANK-700 - Anokion, BMS

https://www.businesswire.com/news/home/20240917374019/en/Anokion-Announces-New-Data-from-the-Phase-1-MoveS-it-Study-Supporting-ANK-700-as-a-Novel-Potential-Disease-Modifying-Treatment-for-Relapsing-Remitting-Multiple-Sclerosis

Sep 18, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next